• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

FDA grants 501(k) clearance to CorNeat Vision’s EverPatch


EverPatch is described by the company as the world's first non-degradable, synthetic tissue substitute for ophthalmic surgery.

(Image Credit: AdobeStock/Postmodern Studio)

(Image Credit: AdobeStock/Postmodern Studio)

CorNeat Vision announced the US Food & Drug Administration (FDA) has granted 501(k) clearance to the company’s EverPatch.

In a press release from CorNeat Vision,1 the CorNeat EverPatch is described as “the first synthetic, non-degradable tissue-integrating matrix for use in ophthalmic surgeries,” and is composed “a non-woven, polymer matrix which integrates with surrounding tissue and is intended to reinforce the sclera and aid the physical reconstruction of the ocular surface.”

According to the company, the CorNeat EverPatch is “poised to displace the use of donor and processed tissue, commonly utilized in ocular surgeries but posing the risk of disease transmission.”

Gilad Litvin, MD, CorNeat Vision’s Chief Medical Officer and Co-Founder discussed the goals of the CorNeat EverPatch in the press release from the company.

"The ideal graft material should be long-lasting, sterile, immunologically inactive, cosmetically acceptable, and readily available. The CorNeat EverPatch was designed with these goals in mind,” said Litvin., “Our novel ophthalmic patch is significantly thinner than processed patch tissue, provides better handling as it does not 'cheesewire' when sutured, and has holes that allow for accurate positioning and anchoring. These holes also facilitate direct conjunctival adhesion to the sclera thus supporting its bio-integration.”

left - CorNeat EverPatch; right - CorNeat EverPatch implanted under the conjunctiva, 9 months post implantation. (Photo Courtesy CorNeat Vision)

left - CorNeat EverPatch; right - CorNeat EverPatch implanted under the conjunctiva, 9 months post implantation. (Photo Courtesy CorNeat Vision)

Almog Aley-Raz, CorNeat Vision’s CEO and VP R&D, talked about the technology behind the CorNeat EyePatch in the release.

“It is the first device that leverages the EverMatrix™, our core tissue-integrating material platform technology, originally developed for our corneal prosthesis program,” said Aley-Raz. “EverMatrix™ presents a significant business opportunity as it is the only synthetic non-degradable patch material in ocular surgery. This biocompatible material has the potential for wider use in soft tissue reinforcement, biomechanical integration of implants with surrounding tissue, fabrication of membranes, and concealment of implants and sensors.

The company states the CorNeat EverPatch will be launched initially in leading ophthalmic centers in the US in Q3 2023, expanding nationwide later in the year.

  1. FDA Clears CorNeat EverPatch, World's First Non-degradable, Synthetic Tissue Substitute for Ophthalmic Surgery. Press Release. CorNeat Vision; June 12, 2023. Accessed June 12, 2023. https://www.prnewswire.com/news-releases/fda-clears-corneat-everpatch-worlds-first-non-degradable-synthetic-tissue-substitute-for-ophthalmic-surgery-301847803.html
Related Videos
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
Elizabeth Yeu, MD, highlights from a corneal case report for a patient undergoing the triple procedure
© 2024 MJH Life Sciences

All rights reserved.